LAKE FOREST, Calif.--(BUSINESS WIRE)--Apr 23, 2012-- ReVision Optics(R), Inc. (RVO), a leader in implantable microlens technology to treat presbyopia, today announced the appointment of the esteemed vision correction expert Stephen Slade, M.D., FACS, to the Company's Board of Directors.
"Dr. Slade is a major force in the field of ophthalmology and a renowned expert in treating patients who require vision correction such as presbyopia. We are delighted to have him join our Board and look forward to his contributions," said J. Randy Alexander, Chairman of the Board of ReVision Optics. "Dr. Slade has pioneered many of the latest technologies for vision correction in use today. Eye surgery patients from around the world seek his professional services and, remarkably, more than 450 of his fellow eye surgeons have chosen him to perform surgery on them. Dr. Slade brings to ReVision Optics a wealth of knowledge, regulatory expertise and industry contacts that will be highly beneficial as we pursue FDA approval to market our PresbyLens(R) microlens." Commenting on his appointment, Dr. Slade said, "I'm delighted to be joining the ReVision Optics Board of Directors, as I believe that the PresbyLens microlens presents an innovative, viable solution to the growing number of individuals with presbyopia who are looking to improve near and intermediate vision without reliance on glasses or contact lenses." Dr. Slade is an active researcher and the U.S. medical monitor for several new technologies, and has been a consultant on many FDA clinical trials. In addition to his position at Slade & Baker Vision Center of Houston, Tex., Dr. Slade is Chief Medical Editor of Cataract and Refractive Surgery Today. In 1991, Dr. Slade and Stephen Brint, M.D., performed the first LASIK procedure in the U.S. and later performed the first Custom LASIK ablation-based on topography in the U.S. He also was the first to perform and has the longest experience with all-laser LASIK, laser cataract surgery and the accommodating IOL for presbyopia, the crystalens.
Dr. Slade was elected president of the American-European Congress of Ophthalmic Surgery in January 2011 and is a Fellow of the American Academy of Ophthalmology and the American College of Surgeons. He was named a Leading Ophthalmologist in America by Becker's ASC Review. He is an active teacher of surgical techniques and has lectured and certified more than 8,000 physicians on LASIK and lamellar refractive surgery. Dr. Slade has received numerous awards including 11 named lectures, Refractive Surgeon of the Year, two China Service Medals, the Summit Technologies Pioneer of Refractive Surgery Award, the Casebeer Award and the Lans Lectureship. In 2007 he received the Barraquer Award, the highest award from the largest society of refractive surgeons. Dr. Slade was selected by his peers for both "Best Doctors" and "Best Doctors in America," and has received the Honor Award of the American Academy of Ophthalmology.
Dr. Slade has served on several editorial boards including the Journal of Refractive Surgery. He has appeared in numerous news segments aired on CBS, ABC, NBC and PBS, and was the featured surgeon on the Emmy Award-winning PBS documentary "20/10 by 2010?" narrated by Walter Cronkite. He holds four patents or patent applications in the field of ophthalmology, and has authored nine textbooks on refractive surgery.
He attended Tulane University and the University of Texas Medical School with a final, elective year at Guy's Hospital, London.
About PresbyLens The PresbyLens is a corneal inlay implanted into a patient's non-dominant eye that is designed to improve near and intermediate vision by microscopically changing the shape of the eye's surface. The microlens is made of medical grade hydrogel similar to contact lenses.
The microlens is mostly water, as is the cornea, and has optical characteristics almost identical to the cornea. The PresbyLens is less than half the thickness of a human hair and has a diameter of only 2 millimeters, about the same as a pinhead. The inlay is bioengineered to facilitate transport of nutrients and fluid and is as transparent as natural tears.
About ReVision Optics ReVision Optics, Inc. focuses on the research and development of custom optical solutions dedicated to vision correction. RVO's first product is the PresbyLens* inlay, a unique patented refractive surgery solution. This inlay is designed to improve the near vision that has been lost by the eye's natural aging process called presbyopia. The PresbyLens inlay is removable, and provides an ideally suited surgical option for near and intermediate vision enhancement.
The Company is actively pursuing regulatory approvals and market opportunities for the PresbyLens worldwide. The PresbyLens has its CE mark and is approved in Europe.
*CAUTION: Investigational device. Limited by Federal (United States) law to investigational use.
CONTACT: COMPANY CONTACT ReVision Optics John Kilcoyne, President & CEO 949-707-2740 firstname.lastname@example.org or MEDIA CONTACT LHA Jody Cain, 310-691-7100 email@example.com @LHA_IR_PR KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: SURGERY HEALTH MEDICAL DEVICES OPTICAL SOURCE: ReVision Optics Copyright Business Wire 2012 PUB: 04/23/2012 08:00 AM/DISC: 04/23/2012 08:00 AM http://www.businesswire.com/news/home/20120423005131/